Toxicity and phototoxicity of Hypocrellin A on malignant human cell lines, evidence of a synergistic action of photodynamic therapy with Imatinib mesylate

Journal of Photochemistry and Photobiology B: Biology

Volumn 99, Issue 2, 2010, Pages 100-104

  Chio Srichan, Sirinart ^a   Oudrhiri, Noufissa ^b   Bennaceur Griscelli, Annelise ^b   Turhan, Ali G ^b,c   Dumas, Paul ^a   Refregiers, Matthieu ^a  

^a SYNCHROTRON SOLEIL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c UNIVERSITÉ DE POITIERS   (France)

Author keywords

Hypocrellin A; Imatinib mesylate.; Photodynamic therapy

Indexed keywords

HYPOCRELLIN A; IMATINIB;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN K 562; CONTROLLED STUDY; DOSIMETRY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; EPITHELIUM TUMOR; HELA CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; PHENOTYPE; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PHOTOTOXICITY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HELA CELLS; HUMANS; K562 CELLS; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PIPERAZINES; PYRIMIDINES; QUINONES;

EID: 77951256785     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2010.03.001     Document Type: Article

References (36)

1. Hamblin M.R., Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease?. Photochem. Photobiol. Sci. 2004, 3:436-450.
2. Oschner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J. Photochem. Photobiol. B 1997, 39:1-18.
3. Vicente M.G. Porphyrin-based sensitizers in the detection and treatment of cancer: recent progress. Curr. Med. Chem. Anticancer Agents 2001, 1:175-194.
4. Tschen E.H., Wong D.S., Pariser D.M., Dunlap F.E., Houlihan A., Ferdon M.B. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br. J. Dermatol. 2006, 155:1262-1269.
5. Rosenfeld P.J., Rich R.M., Lalwani G.A. Ranibizumab: phase III clinical trial results. Ophthalmol. Clin. North Am. 2006, 19:361-372.
6. Overholt B., Lightdale C., Wang K., Canto M., Burdick S., Haggitt R., Bronner M., Taylor S., Grace M., Depot M. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest. Endosc. 2005, 62:488-498.
7. Brown G.C., Brown M.M., Campanella J., Beauchamp G.R. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - a value - based reappraisal with 5-year data. Am. J. Ophthalmol. 2005, 140:679-687.
8. Ayaru L., Bown S.G., Pereira S.P. Photodynamic therapy for pancreatic carcinoma: experimental and clinical studies. Photodiagnosis Photodyn. Ther. 2004, 1:145-155.
9. Freche C., De Corbiere S. Use of photodynamic therapy in the treatment of vocal cord carcinoma. J. Photochem. Photobiol. B 1990, 6:291-296.
10. Maier A., Tomaselli F., Matzi V., Rehak P., Pinter H., Smolle-Jüttner F.M. Photosensitization with hematoporphyrin derivative compared to 5-aminolaevulinic acid for photodynamic therapy of esophageal carcinoma. Ann. Thorac. Surg. 2001, 72:1136-1140.
11. Diwu Z. Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Photochem. Photobiol. 1995, 61:529-539.
12. Ali S.M., Chee S.K., Yuen G.Y., Olivo M. Hypericin and hypocrellin induced apoptosis in human mucosal carcinoma cells. J. Photochem. Photobiol. B 2001, 65:59-73.
13. Zhenjun D., Lown J.W. Hypocrellins and their use in photosensitization. Photochem. Photobiol. 1990, 52:609-616.
14. Cheng L.S., Wang J.Z., Fu S.M. Effect of hypocrellin A sensitization on the lateral mobility of cell membrane proteins. J. Photochem. Photobiol. B 1988, 2:395-398.
15. Cao E.H., Xin S.M., Cheng L.S. DNA damage induced by hypocrellin-A photosensitization. Int. J. Radiat. Biol. 1992, 61:213-219.
16. Kocanova S., Hornakova T., Hritz J., Jancura D., Chorvat D., Mateasik A., Ulicny J., Refregiers M., Maurizot J.-C., Miskovsky P. Characterization of the Interaction of Hypericin with Protein Kinase C in U-87 MG Human Glioma Cells. Photochem. Photobiol. 2006, 82:720-728.
17. Kascakova S S., Refregiers M., Jancura D., Sureau F., Maurizot J.-C., Miskovsky P. Fluorescence spectroscopic study of hypericin-photosensitized oxidation of low-density lipoproteins. Photochem. Photobiol. 2007, 81:1395-1403.
18. Chio-Srichan S., Refregiers M., Jamme F., Rouam V., Dumas P. Photosensitizer effects on cancerous cells: a combined study using synchrotron infrared and fluorescence microscopies. Biochim. Biophys. Acta 2008, 5:854-860.
19. Miller G.G., Brown K., Moore R.B., Diwu Z.J., Liu J., Huang L., Lown J.W., Begg D.A., Chlumecky V., Tulip J., McPhee M.S. Uptake kinetics and intracellular localisation of Hypocrellin photosensitizers for photodynamic therapy: a confocal microscopy study. Photochem. Photobiol. 1995, 61:632-638.
20. Ali S.M., Olivo M. Efficacy of hypocrellin pharmacokinetics in phototherapy. Int. J. Oncol. 2002, 2:1229-1237.
21. Cao E., Cheng L. DNA single-strand breakage and its rejoining in HeLa cells caused by Hypocrellin A photosensitization. Acta Biol. Exp. Sin. 1988, 21:79-85.
22. Dong C., Jia H., Zhang L., Ma C. The inhibitory effect of the new photosensitizer hypocrellin A on experimental tumors. Sheng Wu Hua Hsueh Tsa Chih 1987, 3:468-472.
23. Zhang J., Cao E.H., Li J.F., Zhang T.C., Ma W.J. Photodynamic effects of hypocrellin A on three human malignant cell lines by inducing apoptosis cell death. Photochem. Photobiol. 1998, 43:106-111.
24. Deutsch E., Maggiorella L., Wen B., Bonnet M.L., Khanfir K., Frascogna V., Turhan A.G., Bourhis J. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-ABL expressing cells and decreases AKT phosphorylation. Br. J. Cancer. 2004, 91:1735-1741.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
26. Bruggisser R., von Daeniken K., Jundt G., Schaffner W., Tullberg-Reinert H. Interference of plant extracts phytoestrogens and antioxidants with the MTT tetrazolium assay. Planta Med. 2002, 68:445-448.
27. Smith F.E. Tetrazolium salts. Science 1951, 751-754.
28. Nachbaur D.M., Denz H.A., Gastl G., Thaler J., Lechleitner M., Braunsteiner H. Combination effects of human recombinant interferon (alpha-2-arg, gamma) and cytotoxic agents on colony formation of human melanoma and hypernephroma cell lines. Cancer Lett. 1989, 44:49-53.
29. Jiang X.Y., Zhao Y., Smith C., Gasparetto M., Saw K.M., Turhan A.G., Eaves A., Eaves C. Chronic myeloid leukemia stem cells possess unique properties that predict intrinsic and acquired resistance to imatinib mesylate. Leukemia 2007, 21:926-935.
30. Ossard-Receveur A., Bernheim A., Clausse B., Danglot G., Fauvet D., Leon B., Lozach F., Bories D., Brouzes C., Bourhis J.H., Turhan A.G. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia. Cancer Genet. Cytogenet. 2005, 163:189-190.
31. Sorel N., Bonnet M.L., Guillier M., Guilhot F., Brizard A., Turhan A.G. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem. Biophys. Res. Commun. 2004, 323:728-730.
32. Tipping A.J., Mahon F.X., Zafirides G., Lagarde V., Goldman J.M., Melo J.V. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002, 16:2349-2357.
33. Paterson S.C., Smith K.D., Holyoake T.L., Jørgensen H.G. Is there a cloud in the silver lining for imatinib?. Br. J. Cancer 2003, 88:983-987.
34. Ross D.M., Hughes T.P. Cancer treatment with kinase inhibitors: what have we learnt from imatinib?. Br. J. Cancer 2004, 90:12-19.
35. Edelson R., Berger C., Gasparro F., Jegasothy B., Heald P., Wintroub B., Vonderheid E., Knobler R., Wolff K., Plewig G., Mc Kierman G., Christensen I., Oster M., Hönigsmann H., Wilford H., Kokoschka E., Rehle T., Perez M.I., Stingl G., Laroche L. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N. Eng. J. Med. 1987, 316:297-303.
36. Yang H., Eaves C., de Lima M., Lee M.S., Champlin R.E., McMannis J.D., Robinson S.N., Niu T., Decker W.K., Xing D., Ng J., Li S., Yao X., Eaves A.C., Jones R., Andersson B.S., Shpall E.J. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. Bone Marrow Transplant. 2006, 37:575-582.